Hence, in this study we used a syngeneic PC mouse model and tested the synergistic impact of tripartite treatment by combining fractionated RT, tumor targeted HT, and anti-OX40 immunotherapy (p < 0.001), with no tumor regrowth compared to non-treated animals as control group. The gene discussed is TNFRSF4; the disease is neoplasm.